Market Overview

See Martin Shkreli Analyze Valeant: Live

Related VRX
5 Biggest Price Target Changes For Wednesday
Vetr Thinks Regeneron Is Looking Healthy
Valeant: The Salix Sale Debacle (Seeking Alpha)

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are off almost 50 percent on Tuesday after the company issued poor earnings and guidance, all while reaffirming the SEC is still probing its operations. Ex-pharma exec-turned hedge fund manager-turned FBI fraud target Martin Shkreli is analyzing the company, live on his YouTube channel.

As several comments point out, Shkreli is going through Valeant's financials on Microsoft Excel, talking everything from Philidor to drug sales.

Related Link: Some On Wall Street Still Back Valeant

Valeant shares appear unaffected by Shkreli's commentary. The broadcast concludes at 4 p.m. ET; the full broadcast is expected to be replayable then.

Posted-In: Martin ShkreliAnalyst Color Biotech Hedge Funds Movers General


Related Articles (VRX)

View Comments and Join the Discussion!